KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Payables (2016 - 2025)

Travere Therapeutics' Payables history spans 15 years, with the latest figure at $24.8 million for Q4 2025.

  • For Q4 2025, Payables rose 5.38% year-over-year to $24.8 million; the TTM value through Dec 2025 reached $24.8 million, up 5.38%, while the annual FY2025 figure was $24.8 million, 5.38% up from the prior year.
  • Payables reached $24.8 million in Q4 2025 per TVTX's latest filing, up from $18.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $41.7 million in Q4 2023 to a low of $5.8 million in Q3 2021.
  • Average Payables over 5 years is $18.8 million, with a median of $17.8 million recorded in 2022.
  • Peak YoY movement for Payables: surged 141.04% in 2023, then tumbled 43.53% in 2024.
  • A 5-year view of Payables shows it stood at $15.1 million in 2021, then increased by 14.17% to $17.3 million in 2022, then soared by 141.04% to $41.7 million in 2023, then crashed by 43.53% to $23.5 million in 2024, then grew by 5.38% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Payables are $24.8 million (Q4 2025), $18.2 million (Q3 2025), and $19.1 million (Q2 2025).